These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 21384656)

  • 1. [Neuromuscular blockade after a chain of two laparotomies in a few hours].
    Yamazaki Y; Saito A; Takahashi H
    Masui; 2011 Feb; 60(2):199-202. PubMed ID: 21384656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade.
    Abrishami A; Ho J; Wong J; Yin L; Chung F
    Anesth Analg; 2010 Apr; 110(4):1239. PubMed ID: 20357160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopyrrolate and edrophonium-atropine.
    Sacan O; White PF; Tufanogullari B; Klein K
    Anesth Analg; 2007 Mar; 104(3):569-74. PubMed ID: 17312210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type I second-degree AV block after neostigmine administration in a child with renal failure.
    Webb MD
    Anesth Prog; 1995; 42(1):21-2. PubMed ID: 8934958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neostigmine-induced prolonged neuromuscular blockade in a patient with atypical pseudocholinesterase.
    Ramirez JG; Sprung J; Keegan MT; Hall BA; Bourke DL
    J Clin Anesth; 2005 May; 17(3):221-4. PubMed ID: 15896593
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial.
    Khuenl-Brady KS; Wattwil M; Vanacker BF; Lora-Tamayo JI; Rietbergen H; Alvarez-Gómez JA
    Anesth Analg; 2010 Jan; 110(1):64-73. PubMed ID: 19713265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Conversion to 2nd degree from 1st degree atrioventricular (AV) block by the reversal of neuromuscular blockade].
    Tanaka H; Murata K; Sera A; Horibe M; Izumi H; Tsuchiya T
    Masui; 1991 Apr; 40(4):616-21. PubMed ID: 2051590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Marked prolongation of the succinylcholine effect two hours after neostigmine reversal of neuromuscular blockade in a patient with chronic renal insufficiency.
    Williams AR; Bailey M; Joye T; Burt N
    South Med J; 1999 Jan; 92(1):77-9. PubMed ID: 9932834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: results of a randomised, controlled trial.
    Blobner M; Eriksson LI; Scholz J; Motsch J; Della Rocca G; Prins ME
    Eur J Anaesthesiol; 2010 Oct; 27(10):874-81. PubMed ID: 20683334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neostigmine injected 5 minutes after low-dose rocuronium accelerates the recovery of neuromuscular function.
    Lederer W; Reiner T; Khuenl-Brady KS
    J Clin Anesth; 2010 Sep; 22(6):420-4. PubMed ID: 20868962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emergency use of sugammadex after failure of standard reversal drugs.
    Lenz A; Hill G; White PF
    Anesth Analg; 2007 Mar; 104(3):585-6. PubMed ID: 17312213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical implications of new neuromuscular concepts and agents: so long, neostigmine! So long, sux!
    Lee C; Katz RL
    J Crit Care; 2009 Mar; 24(1):43-9. PubMed ID: 19272538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block.
    Schaller SJ; Fink H; Ulm K; Blobner M
    Anesthesiology; 2010 Nov; 113(5):1054-60. PubMed ID: 20885293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring.
    Illman HL; Laurila P; Antila H; Meretoja OA; Alahuhta S; Olkkola KT
    Anesth Analg; 2011 Jan; 112(1):63-8. PubMed ID: 20978247
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamics of rocuronium 0.3 mg kg(-1) in adult patients with and without renal failure.
    Robertson EN; Driessen JJ; Vogt M; De Boer H; Scheffer GJ
    Eur J Anaesthesiol; 2005 Dec; 22(12):929-32. PubMed ID: 16318664
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deafness and prolonged neuromuscular blockade following single-dose peritoneal neomycin irrigation.
    Gilbert TB; Jacobs SC; Quaddoura AA
    Can J Anaesth; 1998 Jun; 45(6):568-70. PubMed ID: 9669013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex.
    White PF; Tufanogullari B; Sacan O; Pavlin EG; Viegas OJ; Minkowitz HS; Hudson ME
    Anesth Analg; 2009 Mar; 108(3):846-51. PubMed ID: 19224792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of prolonged rocuronium neuromuscular blockade with sugammadex in an obstetric patient with transverse myelitis.
    Weekes G; Hayes N; Bowen M
    Int J Obstet Anesth; 2010 Jul; 19(3):333-6. PubMed ID: 20627694
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coronary vasospasm during the reversal of neuromuscular block using neostigmine.
    Kido K; Mizuta K; Mizuta F; Yasuda M; Igari T; Takahashi M
    Acta Anaesthesiol Scand; 2005 Oct; 49(9):1395-6. PubMed ID: 16146484
    [No Abstract]   [Full Text] [Related]  

  • 20. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial.
    Pühringer FK; Rex C; Sielenkämper AW; Claudius C; Larsen PB; Prins ME; Eikermann M; Khuenl-Brady KS
    Anesthesiology; 2008 Aug; 109(2):188-97. PubMed ID: 18648227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.